U.S. orphan drugs with patents and orphan drug exclusivity as of 2018, by duration
This statistic depicts the number of orphan drugs in the U.S. that were protected by patents or other distinctions as of 2018, by duration of patents or orphan drug exclusivity. According to the data, among those drugs that were still protected by ODE (orphan drug exclusivity) and patent exclusivity, 156 had patents that were longer than their orphan drug exclusivity.